WRN and adult T-cell leukemia/lymphoma: The WRN inhibitors NSC 19630 and NSC 617145 efficiently kill HTLV-1-transformed and patient-derived cells, suggesting that WRN helicases represent a novel therapeutic target for ATLL patients.